Abstract
In the vast majority of studies conducted to date, activation of cancer-specific T cell immunity through peptide-based immunization has failed to induce objective tumor regression. This failure is particularly troublesome given that these vaccines often stimulate T cell responses. In this review, we attempt to understand the relative failure of peptide cancer vaccines to achieve clinically meaningful responses. In the first part of the review, we discuss specific hurdles to successful application of synthetic peptide-based vaccines including patient variability and epitope selection. In the second part of this review, we summarize the importance of CD4+ T cell help in peptide-based vaccine strategies and offer a potential strategy to improve peptide-based vaccines through the generation of both HLA class I and class II vaccine specific-immune responses.
Keywords: Cancer, immunotherapy, HLA class, resolvins I, HLA class II, synthetic peptide, tumor antigen, CTL, T helper cell
Current Molecular Medicine
Title: Synthetic Peptide-Based Cancer Vaccines: Lessons Learned and Hurdles to Overcome
Volume: 9 Issue: 6
Author(s): Caroline J. Voskens, Scott E. Strome and Duane A. Sewell
Affiliation:
Keywords: Cancer, immunotherapy, HLA class, resolvins I, HLA class II, synthetic peptide, tumor antigen, CTL, T helper cell
Abstract: In the vast majority of studies conducted to date, activation of cancer-specific T cell immunity through peptide-based immunization has failed to induce objective tumor regression. This failure is particularly troublesome given that these vaccines often stimulate T cell responses. In this review, we attempt to understand the relative failure of peptide cancer vaccines to achieve clinically meaningful responses. In the first part of the review, we discuss specific hurdles to successful application of synthetic peptide-based vaccines including patient variability and epitope selection. In the second part of this review, we summarize the importance of CD4+ T cell help in peptide-based vaccine strategies and offer a potential strategy to improve peptide-based vaccines through the generation of both HLA class I and class II vaccine specific-immune responses.
Export Options
About this article
Cite this article as:
Voskens J. Caroline, Strome E. Scott and Sewell A. Duane, Synthetic Peptide-Based Cancer Vaccines: Lessons Learned and Hurdles to Overcome, Current Molecular Medicine 2009; 9 (6) . https://dx.doi.org/10.2174/156652409788970724
DOI https://dx.doi.org/10.2174/156652409788970724 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imaging in Inflammatory Bowel Disease Mucosal Healing in Ulcerative Colitis: Relevance for Clinical Outcomes
Current Drug Targets Severe Preeclampsia
Current Women`s Health Reviews Overview
Mini-Reviews in Medicinal Chemistry Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques
Current Bioactive Compounds Hematopoietic Progenitor and Stem Cells Circulate by Surfing on Intracellular Ca2+ Waves: A Novel Target for Cell-based Therapy and Anti-cancer Treatment?
Current Signal Transduction Therapy Genome-wide Differential-based Analysis of the Relationship between DNA Methylation and Gene Expression in Cancer
Current Bioinformatics Dry Powder form of Polymeric Nanoparticles for Pulmonary Drug Delivery
Current Pharmaceutical Design Emerging Therapeutic Approaches Multi-Targeting Receptor Tyrosine Kinases and G Protein-Coupled Receptors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Calcium Phosphate System for Gene Delivery: Historical Background and Emerging Opportunities
Current Pharmaceutical Design Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Towards Characterization of the Human Urinary Peptidome
Combinatorial Chemistry & High Throughput Screening Serum MicroRNA-21 as a Biomarker for Allergic Inflammatory Disease in Children
MicroRNA Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets Network-based Assessment on Chemical-induced Cholestatic Liver Injury
Current Topics in Medicinal Chemistry Nanoparticles-Based Treatment for Bone Metastasis
Current Drug Targets Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design Antiestrogenic Therapies in Solid Cancers and Multiple Myeloma
Current Molecular Medicine Potential Roles of Siglecs in the Regulation of Allo-Immune Reaction
Current Protein & Peptide Science Safety and Utilization of Blood Components as Therapeutic Delivery Systems
Current Pharmaceutical Biotechnology